Liquidia
Liquidia
LQDA
NASDAQ
13.80
USD
-1.64%
About
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD.
YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.7M |
| Three Month Average Volume | 24.8M |
| High Low | |
| Fifty-Two Week High | 16.99 USD |
| Fifty-Two Week Low | 5.71 USD |
| Fifty-Two Week High Date | 22 Mar 2024 |
| Fifty-Two Week Low Date | 19 Oct 2023 |
| Price and Volume | |
| Current Price | 9.51 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -19.84% |
| Thirteen Week Relative Price Change | -30.96% |
| Twenty-Six Week Relative Price Change | -40.43% |
| Fifty-Two Week Relative Price Change | 10.47% |
| Year-to-Date Relative Price Change | -33.24% |
| Price Change | |
| One Day Price Change | -0.31% |
| Thirteen Week Price Change | -26.11% |
| Twenty-Six Week Price Change | -34.50% |
| Five Day Price Change | -4.61% |
| Fifty-Two Week Price Change | 38.43% |
| Year-to-Date Price Change | -20.95% |
| Month-to-Date Price Change | -20.29% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.68911 USD |
| Book Value Per Share (Most Recent Quarter) | 0.82081 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.58226 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.72655 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.35892 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.26907 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.21023 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.20784 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.56988 USD |
| Normalized (Last Fiscal Year) | -1.17229 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.20784 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.56988 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.20784 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.56988 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.21928 USD |
| Cash Per Share (Most Recent Quarter) | 1.74172 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.18476 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.56837 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.2419 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -402 |
| Cash Flow Revenue (Trailing Twelve Months) | -591 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -755.46% |
| Pretax Margin (Last Fiscal Year) | -448.89% |
| Pretax Margin (5 Year) | -474.59% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 83.49% |
| Gross Margin (Trailing Twelve Months) | 69.52% |
| Gross Margin (5 Year) | 82.18% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -432.84% |
| Operating Margin (Trailing Twelve Months) | -733.21% |
| Operating Margin (5 Year) | -463.21% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -448.89% |
| Net Profit Margin (Trailing Twelve Months) | -755.46% |
| Net Profit Margin (5 Year) | -474.59% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -10.56% |
| Tangible Book Value (5 Year) | 16.42% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -23.55% |
| Revenue Growth (3 Year) | 45.23% |
| Revenue Change (Trailing Twelve Months) | -16.65% |
| Revenue Per Share Growth | 9.12% |
| Revenue Growth (5 Year) | 187.02% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 66.93% |
| Total Debt (5 Year) | 29.32% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -0.71% |
| EPS Change (Trailing Twelve Months) | -99.52% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 18 |
| Price to Tangible Book (Most Recent Quarter) | 13 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -47,175,000 |
| Net Debt (Last Fiscal Year) | -37,475,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 42 |
| Price to Sales (Trailing Twelve Months) | 49 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 14 |
| Price to Book (Most Recent Quarter) | 12 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 92 |
| Long Term Debt to Equity (Most Recent Quarter) | 130 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | 6 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -52,854,000 |
| Free Cash Flow (Trailing Twelve Months) | -87,665,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -26 |
| Net Interest Coverage (Trailing Twelve Months) | -29 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 98 |
| Total Debt to Equity (Most Recent Quarter) | 137 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -63.43% |
| Return on Assets (Trailing Twelve Months) | -75.00% |
| Return on Assets (5 Year) | -55.02% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -114.01% |
| Return on Equity (Trailing Twelve Months) | -181.73% |
| Return on Equity (5 Year) | -88.71% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -71.31% |
| Return on Investment (Trailing Twelve Months) | -87.85% |
| Return on Investment (5 Year) | -62.69% |